New Advances in Arbovirus Vaccines

A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Viral Immunology, Vaccines, and Antivirals".

Deadline for manuscript submissions: closed (31 July 2024) | Viewed by 1206

Special Issue Editor


E-Mail Website
Guest Editor
Infectious Disease Center, Shenzhen Bay Laboratory, Shenzhen, China
Interests: virus evolution and transmission; arboviruses; vaccines
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Arboviruses, predominantly transmitted by arthropods, like mosquitoes and ticks, represent a significant public health concern globally. With notorious representatives, such as Dengue, Zika, Chikungunya, Yellow fever, and West Nile viruses, their prevalence and potential for epidemic outbreaks have intensified the urgency for effective preventative measures. At this moment, there is no specific treatment, and there are few licensed vaccines to fight these viruses. The complex landscape of vaccine development is further riddled with challenges like immune enhancement, cross-reactivity, and the adaptive nature of these viruses. Recently, novel platforms, such as mRNA, subunit, virus-like particle, and insect-specific vaccines, have shown promising potential. This Special Issue underscores the progression and evaluation of new vaccine candidates against arboviruses, with special focus on vaccines developed using new strategies. Submissions of original research articles and reviews are welcome, but not limited, to the following diseases: Dengue, Chikungunya, Zika, Yellow fever, Japanese encephalitis, West Nile, Equine Encephalitis and Crimean–Congo haemorrhagic fever virus.

Dr. Jianying Liu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • arboviruses
  • vaccine development
  • antibody-dependent enhancement
  • cross-reactivity
  • mRNA vaccines
  • insect-specific vaccines
  • virus-like particle
  • transmission-blocking vaccines

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

20 pages, 4339 KiB  
Article
Cross-Neutralizing Anti-Chikungunya and Anti-Dengue 2 IgG Antibodies from Patients and BALB/c Mice against Dengue and Chikungunya Viruses
by Araceli Posadas-Mondragón, José Angel Santiago-Cruz, Angélica Pérez-Juárez, Norma Estela Herrera-González, Sara M. Sosa-Delgado, Claudia Elena Wong-Arámbula, Abril Paulina Rodríguez-Maldonado, Mauricio Vázquez-Pichardo, Daniel Duran-Ayala and José Leopoldo Aguilar-Faisal
Viruses 2024, 16(7), 1098; https://doi.org/10.3390/v16071098 - 8 Jul 2024
Viewed by 432
Abstract
Dengue (DENV) and Chikungunya (CHIKV) viruses can be transmitted simultaneously by Aedes mosquitoes, and there may be co-infections in humans. However, how the adaptive immune response is modified in the host has yet to be known entirely. In this study, we analyzed the [...] Read more.
Dengue (DENV) and Chikungunya (CHIKV) viruses can be transmitted simultaneously by Aedes mosquitoes, and there may be co-infections in humans. However, how the adaptive immune response is modified in the host has yet to be known entirely. In this study, we analyzed the cross-reactivity and neutralizing activity of IgG antibodies against DENV and CHIKV in sera of patients from the Mexican Institute of Social Security in Veracruz, Mexico, collected in 2013 and 2015 and using IgG antibodies of BALB/c mice inoculated with DENV and/or CHIKV. Mice first inoculated with DENV and then with CHIKV produced IgG antibodies that neutralized both viruses. Mice were inoculated with CHIKV, and then with DENV; they had IgG antibodies with more significant anti-CHIKV IgG antibody neutralizing activity. However, the inoculation only with CHIKV resulted in better neutralization of DENV2. In sera obtained from patients in 2013, significant cross-reactivity and low anti-CHIKV IgG antibody neutralizing activity were observed. In CHIKV-positive 2015 sera, the anti-DENV IgG antibody neutralizing activity was high. These results suggest that CHIKV stimulates DENV2-induced memory responses and vice versa. Furthermore, cross-reactivity between the two viruses generated neutralizing antibodies, but exchanging CHIKV for DENV2 generated a better anti-CHIKV neutralizing response. Full article
(This article belongs to the Special Issue New Advances in Arbovirus Vaccines)
Show Figures

Figure 1

Back to TopTop